• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.

作者信息

Blauvelt A, Rosmarin D, Bieber T, Simpson E L, Bagel J, Worm M, Deleuran M, Katoh N, Kawashima M, Shumel B, Chen Z, Rossi A B, Hultsch T, Ardeleanu M

出版信息

Br J Dermatol. 2019 Jul;181(1):196-197. doi: 10.1111/bjd.17703. Epub 2019 Mar 22.

DOI:10.1111/bjd.17703
PMID:30719707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6850039/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cc/6850039/40493c0e9ff7/BJD-181-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cc/6850039/40493c0e9ff7/BJD-181-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96cc/6850039/40493c0e9ff7/BJD-181-196-g001.jpg

相似文献

1
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.度普利尤单抗治疗特应性皮炎在不同解剖区域的改善效果相同：来自III期临床试验的数据。
Br J Dermatol. 2019 Jul;181(1):196-197. doi: 10.1111/bjd.17703. Epub 2019 Mar 22.
2
Biologics for Atopic Dermatitis.特应性皮炎的生物制剂。
Immunol Allergy Clin North Am. 2020 Nov;40(4):593-607. doi: 10.1016/j.iac.2020.06.004. Epub 2020 Sep 12.
3
Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.度普利尤单抗治疗中重度特应性皮炎患者对循环 T 细胞功能的早期和长期影响。
J Invest Dermatol. 2021 Aug;141(8):1943-1953.e13. doi: 10.1016/j.jid.2021.01.022. Epub 2021 Feb 18.
4
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.评估在2019冠状病毒病大流行期间使用度普利尤单抗治疗特应性皮炎的风险。
J Am Acad Dermatol. 2020 Sep;83(3):e251-e252. doi: 10.1016/j.jaad.2020.06.015. Epub 2020 Jun 10.
5
Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.使用度普利尤单抗治疗特应性皮炎期间，尚伯格病的发作与斑秃的缓解。
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):65-66. doi: 10.18176/jiaci.0541. Epub 2020 Jun 3.
6
Interleukin-4 and anxiety in adults with atopic dermatitis.白细胞介素-4与特应性皮炎成人患者的焦虑症
Acta Neuropsychiatr. 2020 Oct;32(5):271-273. doi: 10.1017/neu.2020.23. Epub 2020 May 11.
7
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).度普利尤单抗单药治疗中重度特应性皮炎成人患者的疗效和安全性：两项 3 期随机临床试验（LIBERTY AD SOLO 1 和 LIBERTY AD SOLO 2）的汇总分析。
J Dermatol Sci. 2019 May;94(2):266-275. doi: 10.1016/j.jdermsci.2019.02.002. Epub 2019 Mar 12.
8
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
9
Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.度普利尤单抗治疗肝移植受者特应性皮炎的有效性和安全性：一例病例报告
J Dtsch Dermatol Ges. 2020 Jul;18(7):740-742. doi: 10.1111/ddg.14074. Epub 2020 Mar 25.
10
Development of Sézary syndrome following the administration of dupilumab.使用度普利尤单抗后发生蕈样肉芽肿综合征。
Dermatol Online J. 2020 Apr 15;26(4):13030/qt1m67z8sb.

引用本文的文献

1
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.使用Stapokibart治疗52周的中度至重度特应性皮炎成人患者的患者报告结局：一项3期试验的事后分析
Adv Ther. 2025 Jul 12. doi: 10.1007/s12325-025-03284-7.
2
A Clinician's Guide to Dupilumab-related Ocular Surface Disease.度普利尤单抗相关眼表疾病临床医生指南
J Clin Aesthet Dermatol. 2025 May 1;18(5):26-28.
3
Real-World Efficacy and Safety of Dupilumab Use in Japanese Adult Patients with Atopic Dermatitis: A Single-Center, Retrospective, 104-Week, Observational Study.

本文引用的文献

1
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).度普利尤单抗联合外用皮质类固醇治疗对环孢素 A 应答不足或不耐受或当这种治疗在医学上不建议时的中重度特应性皮炎成人患者：一项安慰剂对照、随机 III 期临床试验（LIBERTY AD CAFÉ）。
Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.
2
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
度普利尤单抗在日本成年特应性皮炎患者中的真实世界疗效和安全性：一项单中心、回顾性、104周观察性研究。
Diseases. 2025 Feb 3;13(2):44. doi: 10.3390/diseases13020044.
4
Hotspots and development trends of gut microbiota in atopic dermatitis: A bibliometric analysis from 1988 to 2024.特应性皮炎中肠道微生物群的热点与发展趋势：1988年至2024年的文献计量分析
Medicine (Baltimore). 2024 Dec 13;103(50):e40931. doi: 10.1097/MD.0000000000040931.
5
Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single-centre study on 485 patients.特应性皮炎的特殊部位：度普利尤单抗治疗手部的单中心485例患者研究的有效性
Australas J Dermatol. 2024 Dec;65(8):e263-e265. doi: 10.1111/ajd.14372. Epub 2024 Oct 21.
6
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.对于中度至重度特应性皮炎的青少年和成人患者，瑞必克izumab可在所有湿疹面积和严重程度指数的身体部位及临床体征方面迅速产生临床反应。
Dermatol Ther (Heidelb). 2024 May;14(5):1145-1160. doi: 10.1007/s13555-024-01158-4. Epub 2024 May 3.
7
A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.度普利尤单抗治疗婴幼儿特应性皮炎的研究进展。
Drug Des Devel Ther. 2024 Mar 27;18:941-951. doi: 10.2147/DDDT.S457761. eCollection 2024.
8
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.度普利尤单抗治疗可使6个月至5岁患者所有解剖部位的特应性皮炎迅速且持续改善。
Dermatol Ther (Heidelb). 2023 Sep;13(9):1987-2000. doi: 10.1007/s13555-023-00960-w. Epub 2023 Jul 22.
9
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.在3期JADE COMPARE研究中，使用阿布昔替尼治疗时中重度特应性皮炎体征/症状按身体部位改善的速度
Dermatol Ther (Heidelb). 2022 Mar;12(3):771-785. doi: 10.1007/s13555-022-00694-1. Epub 2022 Mar 17.
10
Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience.巴瑞替尼治疗特应性皮炎：首次真实世界经验
Acta Derm Venereol. 2022 Mar 22;102:adv00677. doi: 10.2340/actadv.v102.1088.
3
Commonality of the IL-4/IL-13 pathway in atopic diseases.特应性疾病中白细胞介素-4/白细胞介素-13通路的共性
Expert Rev Clin Immunol. 2017 May;13(5):425-437. doi: 10.1080/1744666X.2017.1298443. Epub 2017 Mar 15.
4
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.两项度普利尤单抗治疗特应性皮炎的 3 期临床试验。
N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
5
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.精确且原位遗传人源化 6Mb 大小的小鼠免疫球蛋白基因。
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52. doi: 10.1073/pnas.1323896111. Epub 2014 Mar 25.
6
The role of Malassezia in atopic dermatitis affecting the head and neck of adults.马拉色菌在影响成人头颈部特应性皮炎中的作用。
J Am Acad Dermatol. 2009 Jan;60(1):125-36. doi: 10.1016/j.jaad.2008.07.058. Epub 2008 Oct 1.
7
Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas.外用皮质类固醇和外用钙调神经磷酸酶抑制剂在薄嫩及敏感皮肤区域特应性皮炎治疗中的应用。
Curr Med Res Opin. 2008 Apr;24(4):985-94. doi: 10.1185/030079908x280419. Epub 2008 Feb 18.
8
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.湿疹面积及严重程度指数（EASI）：特应性皮炎中的可靠性评估。EASI评估者小组。
Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.